Alkermes plc (ALKS) Event July 27, 2022, 00:00 UTC 33 1 comments (76% Positive) Alkermes plc. (ALKS) Reports 70% Loss Reduction for 2022-06-30 Comment Full text
Scholar Rock Holding Corp (SRRK) Event July 26, 2022, 21:01 UTC 24 1 comments (96% Neutral) Scholar Rock Holding Corporation (SRRK) Provides Update on experience for our first potenti Comment Full text
Supernus Pharmaceuticals Inc (SUPN) Event July 26, 2022, 20:42 UTC 24 1 comments (99% Neutral) Supernus Pharmaceuticals Inc (SUPN) Files Form 8-K Comment Full text
Summit Plc (SMMT) Event July 26, 2022, 20:31 UTC 24 1 comments (10% Negative) Summit Therapeutics Inc. (SMMT) Announces Clinical Trial Timeline Adjustment Comment Full text
Akouos Inc (the company became a subdivision of the company LIlly (LLY)) (AKUS) Event July 26, 2022, 20:25 UTC 24 1 comments (99% Neutral) Akouos, Inc. (AKUS) Announces New Board Appointment Comment Full text
Prometheus Biosciences Inc (company is now a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) (RXDX) Event July 26, 2022, 20:05 UTC 23 1 comments (10% Negative) PROMETHEUS BIOSCIENCES, INC. (RXDX) Announces Clinical Trial Timeline Adjustment Comment Full text
Sutro Biopharma Inc (STRO) Event July 26, 2022, 20:02 UTC 23 1 comments (75% Positive) SUTRO BIOPHARMA, INC. (STRO) Announces Clinical Development Update Comment Full text
BridgeBio Pharma (BBIO) Event July 26, 2022, 12:00 UTC 24 1 comments (99% Neutral) BridgeBio Pharma, Inc. (BBIO) Announces Clinical Development Update Comment Full text
Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023) (ICPT) Event July 26, 2022, 11:30 UTC 24 1 comments (99% Neutral) Intercept Pharmaceuticals, Inc. (ICPT) Announces Update on Collaboration with IRS Employer Comment Full text
IVERIC bio Inc (the company became a subdivision of the company Astellas Pharma Inc. (TSE: 4503)) (ISEE) Event July 26, 2022, 10:36 UTC 24 1 comments (90% Positive) IVERIC bio, Inc. (ISEE) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text